S-1/A: Oaktree Acquisition Corp. III Life Sciences Files Amendment No. 1 to Form S-1 for $175 Million IPO

Oaktree Acquisition Corp. III Life Sciences, a blank check company targeting the healthcare sector, files an amendment to its S-1 registration statement for a $175 million initial public offering.

Summary

• Oaktree Acquisition Corp. III Life Sciences, a newly formed blank check company, is planning an initial public offering (IPO) to raise $175 million.
• The company intends to focus on the healthcare or healthcare-related industries in North America, the United Kingdom and Western Europe.
• Each unit in the IPO is priced at $10.00 and consists of one Class A ordinary share and one-fifth of one redeemable warrant.
• The warrants will be exercisable 30 days after the completion of the initial business combination at a price of $11.50 per share and will expire five years after the completion of the initial business combination.
• The company has 24 months from the closing of the offering to complete a business combination.
• If a business combination is not completed within this timeframe, the public shares will be redeemed.
• The sponsor, Oaktree Acquisition Holdings III LS, LLC, will purchase 550,000 private placement units at $10.00 per unit, totaling $5.5 million.
• The company's management team has experience with previous SPACs, including Hims & Hers Health, Inc. and Alvotech.
• The company intends to apply to list its units on the Nasdaq Global Market under the symbol OACCU.
• The company is an emerging growth company and a smaller reporting company, which allows for reduced reporting requirements.

Sentiment

Score: 7

Explanation: The document presents a balanced view, highlighting both the potential opportunities and risks associated with the investment. The experience of the management team and the affiliation with Oaktree are positive factors, while the nature of a blank check company and potential conflicts of interest are risks to consider.

Positives

• Experienced management team with a track record in healthcare investments and SPAC transactions.
• Focus on a growing and innovative healthcare sector.
• Affiliation with Oaktree Capital Management provides access to a broad network and expertise.
• Units are structured to reduce dilution compared to some other SPACs.
• The company has the ability to extend the time period to consummate the initial business combination.

Negatives

• Blank check company with no operating history or revenues.
• Shareholders may not have the opportunity to vote on the initial business combination.
• Redemption rights of public shareholders may make the company unattractive to potential targets.
• Competition from other SPACs may increase the cost of finding a suitable target.
• Management time may be divided among various business activities, creating potential conflicts of interest.

Risks

• Inability to identify and complete a business combination within the specified timeframe.
• Potential for dilution of shareholder equity through additional share issuances.
• Dependence on management team and potential conflicts of interest.
• Limited ability to evaluate the management of a prospective target business.
• Changes in laws and regulations may adversely affect the business.

Future Outlook

The company intends to focus on industries that complement its management team's background, and to capitalize on the ability of its management team to identify and acquire a business, focusing on the healthcare or healthcare-related industries.

Industry Context

The announcement highlights the ongoing trend of SPACs targeting the healthcare sector, driven by innovation, technological advancements, and favorable demographic trends.

Comparison to Industry Standards

• The document references Oaktree's previous SPAC transactions, Hims & Hers Health, Inc. (NYSE: HIMS) and Alvotech (NASDAQ: ALVO), as examples of successful de-SPACing acquisitions in the healthcare space.
• The document notes that Oaktrees SPACs have generated an equity return of approximately 40% since 2020.
• The document mentions that the life sciences sector is the most active with 168 transactions raising $34 billion in proceeds year-to-date.
• The document states that there is a large backlog of life sciences companies with only 11 IPOs completed year-to-date and 23,000 life sciences company globally and the capital market conditions continue to improve with more IPOs completed in 2024 (year-to-date) than both 2022 and 2023.

Related Party Transactions

• The sponsor will purchase private placement units for $5.5 million.
• The company will pay the sponsor $25,000 per month for office space, secretarial and administrative services.
• The company may reimburse the sponsor, officers, and directors for out-of-pocket expenses.
• The sponsor, affiliates of the sponsor or our officers and directors may, but are not obligated to, loan us funds as may be required to finance transaction costs in connection with an intended initial business combination.

Stakeholder Impact

• Shareholders will have the opportunity to redeem their shares upon completion of the initial business combination.
• Shareholders may experience dilution through additional share issuances.
• The success of the business combination will impact the value of shareholders' investments.
• Employees of the target business may be affected by changes in management or operations.
• Customers and suppliers of the target business may be affected by the business combination.

Next Steps

• The company will seek to identify and evaluate potential target businesses in the healthcare sector.
• The company will negotiate and enter into a definitive agreement for a business combination.
• The company will seek shareholder approval for the business combination, if required.
• The company will complete the business combination and integrate the target business.

Key Dates

Keywords

SPAC, healthcare, business combination, Oaktree, IPO, acquisition, blank check company, life sciences, warrants, units